Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.

Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Börgel J, Mügge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK.

Circulation. 2004 Oct 12;110(15):2132-6.

2.

Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma.

Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Panfilov VI.

Chest. 2007 Jul;132(1):120-6.

PMID:
17475630
3.

The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile.

Börgel J, Bulut D, Hanefeld C, Neubauer H, Mügge A, Epplen JT, Holland-Letz T, Spiecker M.

BMC Cardiovasc Disord. 2008 Dec 23;8:41. doi: 10.1186/1471-2261-8-41.

4.

Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history.

Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, Hung CH, Shin SJ, Chen HJ, Lee YJ.

Exp Clin Endocrinol Diabetes. 2010 Jun;118(6):346-52. doi: 10.1055/s-0029-1243604.

PMID:
20140850
5.

Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction.

Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM, Chen JH.

Atherosclerosis. 2007 Nov;195(1):199-206.

PMID:
17126841
6.

Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease.

Spiecker M, Liao J.

Trends Cardiovasc Med. 2006 Aug;16(6):204-8. Review.

PMID:
16839864
7.

A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population.

Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Ivakin VE, Katargina LN, Kolesnikova OE.

Dis Markers. 2008;24(2):119-26.

8.

A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China.

Zhu Q, Fu Z, Ma Y, Yang H, Huang D, Xie X, Liu F, Zheng Y, Cha E.

Clin Biochem. 2013 Aug;46(12):1047-54. doi: 10.1016/j.clinbiochem.2013.05.003.

9.

Cloning of CYP2J2 gene and identification of functional polymorphisms.

King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L, Spiecker M, Liao JK, Mohrenweiser H, Zeldin DC.

Mol Pharmacol. 2002 Apr;61(4):840-52.

10.

CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC.

Pharmacogenet Genomics. 2007 May;17(5):349-58.

11.

CYP2J2*7 single nucleotide polymorphism in a Chinese population.

Wang H, Jiang Y, Liu Y, Lin C, Cheng G, Chen X, Hao B, Tan W, Lin D, He F.

Clin Chim Acta. 2006 Mar;365(1-2):125-8.

PMID:
16182271
12.

Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia.

Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, Kumar M, Hughes WM Jr, Metreveli N, Rosenberger DS, Singh M, Vacek TP, Rodriguez WE, Ayotunde A, Tyagi SC.

J Cell Physiol. 2008 Jun;215(3):771-81. doi: 10.1002/jcp.21356.

13.

Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease.

Xu Y, Ding H, Peng J, Cui G, Liu L, Cianflone K, Wang DW.

Pharmacogenet Genomics. 2011 Aug;21(8):489-94. doi: 10.1097/FPC.0b013e3283485eb2.

PMID:
21642892
14.

Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors.

Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW.

Cancer Res. 2005 Jun 1;65(11):4707-15.

15.

Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.

King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, Zeldin DC.

Pharmacogenet Genomics. 2005 Jan;15(1):7-13.

PMID:
15864120
16.

Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia.

Herse F, Lamarca B, Hubel CA, Kaartokallio T, Lokki AI, Ekholm E, Laivuori H, Gauster M, Huppertz B, Sugulle M, Ryan MJ, Novotny S, Brewer J, Park JK, Kacik M, Hoyer J, Verlohren S, Wallukat G, Rothe M, Luft FC, Muller DN, Schunck WH, Staff AC, Dechend R.

Circulation. 2012 Dec 18;126(25):2990-9. doi: 10.1161/CIRCULATIONAHA.112.127340.

17.

CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance.

Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, Wu S.

Mol Pharmacol. 1997 Jun;51(6):931-43.

18.

Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids.

Spiecker M, Liao JK.

Arch Biochem Biophys. 2005 Jan 15;433(2):413-20. Review.

PMID:
15581597
19.

Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.

Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, Lee CR.

Atherosclerosis. 2012 Jun;222(2):530-6. doi: 10.1016/j.atherosclerosis.2012.03.022.

20.

Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes.

Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenbergen C, Falck JR, Moomaw CR, Zeldin DC.

J Biol Chem. 1997 May 9;272(19):12551-9.

Supplemental Content

Support Center